Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Operating Margin (2021 - 2024)

Amylyx Pharmaceuticals has reported Operating Margin over the past 4 years, most recently at 6392.14% for Q4 2024.

  • Quarterly results put Operating Margin at 6392.14% for Q4 2024, up 638959.0% from a year ago — trailing twelve months through Sep 2025 was 24739.15% (up 2490305.0% YoY), and the annual figure for FY2024 was 360.1%, down 37029.0%.
  • Operating Margin for Q4 2024 was 6392.14% at Amylyx Pharmaceuticals, up from 18187.74% in the prior quarter.
  • Over the last five years, Operating Margin for AMLX hit a ceiling of 6392.14% in Q4 2024 and a floor of 18187.74% in Q3 2024.
  • Median Operating Margin over the past 4 years was 137.78% (2024), compared with a mean of 3414.35%.
  • Biggest five-year swings in Operating Margin: skyrocketed 1001476bps in 2023 and later plummeted -1820597bps in 2024.
  • Amylyx Pharmaceuticals' Operating Margin stood at 8041.4% in 2021, then surged by 98bps to 167.91% in 2022, then soared by 102bps to 2.55% in 2023, then skyrocketed by 250972bps to 6392.14% in 2024.
  • The last three reported values for Operating Margin were 6392.14% (Q4 2024), 18187.74% (Q3 2024), and 7457.09% (Q2 2024) per Business Quant data.